High-yield points
- Brainstem LGG vs DIPG: focal, exophytic, enhancing, cystic, outside the pons or a long history means think LGG and consider surgery or biopsy (see caveats).
- Tectal glioma: ETV (89% shunt-free) , then MRI surveillance. A quarter need tumor treatment; enhancement, eye-movement signs and spread beyond the tectum predict it .
- Dorsally exophytic: remove the exophytic part only, and stop at the floor of the fourth ventricle .
- Brainstem pilocytic: GTR matters (5-year PFS 74% vs 19%), and survival is excellent either way .
- Biopsy is safe: 96% diagnostic, 0.6% permanent morbidity .
- BRAF V600E: dabrafenib plus trametinib (47% vs 11% response) , which is a real alternative to risky resection .
Landmark papers
- Pollack et al., J Neurosurg 1993: 18 dorsally exophytic brainstem gliomas. Removing the exophytic part, without chasing tumor into the brainstem, controlled most of them long term .
- Kestle et al., J Neurosurg 2004: brainstem pilocytic astrocytoma. 5-year PFS 74% after GTR vs 19% with solid residual tumor, and all patients were alive .
- Bouffet et al., N Engl J Med 2023: dabrafenib plus trametinib vs chemotherapy for BRAF V600 pediatric LGG, with a 47% vs 11% response .
Most pediatric brainstem tumors are diffuse intrinsic pontine gliomas (DIPG) , a subset of diffuse midline glioma that is fatal and not resectable. The rest are focal low-grade gliomas, which have an excellent prognosis and are often surgical. Telling the two apart on MRI is the first job (see DIPG and diffuse midline glioma).
Brainstem LGGs are usually pilocytic astrocytomas or gangliogliomas. The most common molecular change is the KIAA1549–BRAF fusion, followed by BRAF V600E and FGFR alterations .
Patterns that predict behavior
Classification by location and growth pattern guides the surgical plan . A surgical series of 62 children grouped tumors as:
- dorsal exophytic;
- focal brainstem;
- cervicomedullary;
- upper and lower cerebellar peduncular.
Features that favor a low-grade tumor over DIPG (see caveats):
- focal, well-circumscribed margins;
- exophytic growth;
- enhancement and cysts (DIPG is usually non-enhancing at diagnosis);
- a long history of symptoms;
- location outside the pons (tectum, medulla, cervicomedullary junction).
Tectal gliomas
- Indolent tumors of the quadrigeminal plate. They present with hydrocephalus from aqueductal compression.
- Natural history (170 patients, 67 children) :
- hydrocephalus in 84% of children (vs 50% of adults);
- radiographic PFS 90% at 5 years and 86% at 10 years;
- among children with 5 or more years of follow-up, 24% progressed radiographically and 25% needed tumor-directed treatment;
- predictors of needing treatment (univariate): eye-movement abnormalities, extension beyond the tectum, T1 hypointensity, contrast enhancement and growth.
- Radiographic progression didn't always need treatment.
- ETV, not a shunt (31 patients) :
- shunts malfunctioned often, and most needed revision;
- ETV succeeded in all 18 attempts, and 89% stayed shunt-free, whether ETV was first-line or after shunt failure.
- Management: ETV, then serial MRI. Biopsy or treat only if the tumor grows or enhances (see caveats).
Dorsally exophytic tumors
- They fill the fourth ventricle from a broad base on the dorsal brainstem. Histology is usually benign .
- Pollack series (18 children, median follow-up 113 months) :
- the exophytic part was removed, with no attempt to remove tumor from the brainstem floor;
- 16 of 18 were grade I–II astrocytomas;
- only 4 regrew, and all were treated by repeat excision, with radiotherapy in some;
- recurrent tumors stayed histologically benign.
- Conclusion: most can be managed with subtotal excision and CSF diversion if needed.
- Stop at the floor of the fourth ventricle. Chasing tumor into the facial colliculus or vagal trigone causes cranial nerve deficits (see caveats; see neuromonitoring).
Focal intrinsic and cervicomedullary tumors
- Brainstem pilocytic astrocytoma (28 children) :
- PFS after gross total resection (or linear enhancement only): 74% at 5 years, 62% at 10 years;
- with solid residual tumor: 19% at 5 and 10 years;
- all patients were alive at a mean of 6 years;
- new deficits were common right after surgery and often resolved, but 6 of 28 had a lasting deficit.
- Mixed brainstem and peduncular LGGs (62 children) :
- of the 50 tumors excised: GTR 40%, near-total 34%, subtotal 26%;
- PFS 95% at 3 years and 90% at 5 years;
- focal intrinsic tumors were biopsied stereotactically, not resected;
- chemotherapy helped focal, progressive and incompletely resected tumors.
- Cervicomedullary gliomas are usually low-grade. Management has changed little in 40 years, apart from molecular diagnosis, targeted therapy, neuromonitoring and better radiotherapy techniques .
- Surgical approach: enter through the point where the tumor comes closest to the surface, or through a safe entry zone. Use mapping and monitoring of cranial nerve nuclei and the long tracts (see caveats; see brainstem cavernous malformations for safe entry zones).
Biopsy
- Stereotactic biopsy of pediatric brainstem tumors (meta-analysis, 735 procedures) :
- diagnostic success 96.1%;
- overall morbidity 6.7%, permanent morbidity 0.6%, mortality 0.6%.
- Biopsy an atypical lesion whose imaging doesn't fit DIPG and that can't be safely resected. Tissue also gives the molecular target (see caveats).
Targeted therapy
- BRAF V600: dabrafenib plus trametinib beat carboplatin–vincristine as first-line therapy for pediatric LGG (randomized phase 2, 110 patients) :
- response 47% vs 11%;
- median PFS 20.1 vs 7.4 months (HR 0.31);
- grade 3 or higher adverse events 47% vs 94%.
- The trial included LGGs at all sites, not just the brainstem.
- Unresectable cervicomedullary BRAF V600E tumors (4 children) :
- dabrafenib produced rapid, durable regression;
- three tolerated it for up to 9 years.
- The authors suggest upfront BRAF inhibition as an alternative to chemotherapy, radiotherapy or risky resection in selected cases.
- KIAA1549–BRAF fusion tumors respond to MEK inhibitors (see caveats; see supratentorial LGG).
Related topics
- Diffuse Intrinsic Pontine Glioma (DIPG): the main differential.
- Diffuse Midline Glioma, H3 K27-Altered: the molecular entity behind DIPG.
- Pilocytic Astrocytoma (Juvenile Pilocytic Astrocytoma): the commonest histology.
- Supratentorial Low-Grade Glioma and Glioneuronal Tumors: molecular subtypes and targeted therapy.
- Endoscopic Third Ventriculostomy (ETV): hydrocephalus from tectal gliomas.
- Brainstem Cavernous Malformations in Children: safe entry zones and brainstem surgery.
- Tumors of the Pineal Region: tectal and pineal region masses.
- Intraoperative Neuromonitoring Under Anesthesia: Brain and Spine: cranial nerve and tract monitoring.
- Posterior Fossa Tumor Resection: step-by-step procedure.
References
- Lu VM, Jallo GI, Shimony N. Pediatric low-grade brainstem glioma: a review of current diagnosis and treatment paradigms in the molecular era. Childs Nerv Syst 2025;41(1):261. doi:10.1007/s00381-025-06924-z. PMID 40824451. verified
- Rady MR, Enayet AE, Refaat A, et al. Management and outcome of pediatric brainstem and cerebellar peduncular low-grade gliomas: a retrospective analysis of 62 cases. Childs Nerv Syst 2022;38(3):565–575. doi:10.1007/s00381-021-05405-3. PMID 34787716. verified
- Bauman MMJ, Giesken MB, Naylor RM, et al. Predicting disease progression and the need for tumor-directed treatment in tectal plate gliomas. J Neurosurg Pediatr 2023;32(3):332–342. doi:10.3171/2023.4.PEDS22485. PMID 37347621. verified
- Li KW, Roonprapunt C, Lawson HC, et al. Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. Neurosurg Focus 2005;18(6A):E2. PMID 16048288. verified
- Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg 1993;78(6):859–863. doi:10.3171/jns.1993.78.6.0859. PMID 8487066. verified
- Kestle J, Townsend JJ, Brockmeyer DL, Walker ML. Juvenile pilocytic astrocytoma of the brainstem in children. J Neurosurg 2004;101(1 Suppl):1–6. doi:10.3171/ped.2004.101.2.0001. PMID 16206964. verified
- Trezza A, de Laurentis C, Biassoni V, et al. Cervicomedullary gliomas in pediatric age: a systematic review of the literature and tertiary care center experience. Pediatr Neurosurg 2022;57(3):149–160. doi:10.1159/000524165. PMID 35306489. verified
- Hamisch C, Kickingereder P, Fischer M, et al. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr 2017;20(3):261–268. doi:10.3171/2017.2.PEDS1665. PMID 28621573. verified
- Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108–1120. doi:10.1056/NEJMoa2303815. PMID 37733309. verified
- Campino GA, Shrot S, Constantini S, et al. Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation. Childs Nerv Syst 2025;41(1):429. doi:10.1007/s00381-025-07084-w. PMID 41423525. verified
Verification (2026-11-18):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Reference 4 has no DOI on PubMed.
- Numbers were checked against the PubMed abstracts. In reference 2, the 50 excised tumors are the 62 children minus the 12 focal tumors that were biopsied. Reference 5's abstract is truncated on PubMed; the conclusions quoted are from the visible part.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the usual histologies (pilocytic astrocytoma, ganglioglioma);
- the imaging features that favor LGG over DIPG;
- tectal glioma surveillance and when to biopsy or treat;
- stopping at the fourth-ventricle floor and the cranial nerve nuclei at risk;
- entry through the closest surface point or a safe entry zone, and mapping and monitoring;
- when to biopsy an atypical lesion;
- MEK inhibitor responses in BRAF fusion tumors.
- Reference 3 includes adults; its figures here are for the children where stated.
- Reference 10 is four patients.
- The figure is an original schematic.